

Our Ref: 357/2022

September 2022

Re: Your request made under the Freedom of Information Act 2000

I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please answer the following two questions:

Q1. How many patients were treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:

- Abatacept - 0
- Adalimumab – Humira - 2
- Adalimumab Biosimilar - 30
- Apremilast - Unable to answer this question due to Cost Centre
- Bimekizumab - 0
- Brodalumab - 9
- Certolizumab - 2
- Dimethyl fumarate – Unable to answer this question due to Cost Centre
- Etanercept – Enbrel - 1
- Etanercept Biosimilar - 0
- Golimumab - 0
- Guselkumab - 30
- Infliximab – Remicade – Unable to answer this question due to Cost Centre
- Infliximab Biosimilar Unable to answer this question due to Cost Centre
- Ixekizumab - 5
- Risankizumab - 0
- Secukinumab - 65
- Tildrakizumab - 4
- Tofacitinib - 0
- Ustekinumab - 23

Our Ref: 357/2022

September 2022

- Upadacitinib - 0

Q2. How many patients were treated in the last 3 months by the **Dermatology** department for Psoriatic Arthritis (PsA) ONLY with the following biologic drugs:

- Adalimumab - Humira
 - Adalimumab Biosimilar
 - Apremilast
 - Certolizumab
 - Dimethyl fumarate
 - Etanercept - Enbrel
 - Etanercept Biosimilar
 - Guselkumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Ixekizumab
 - Risankizumab
 - Secukinumab
 - Ustekinumab
-
- **Our system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**